Robert Schmouder

6.7k total citations · 2 hit papers
93 papers, 5.4k citations indexed

About

Robert Schmouder is a scholar working on Molecular Biology, Transplantation and Immunology. According to data from OpenAlex, Robert Schmouder has authored 93 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Molecular Biology, 24 papers in Transplantation and 22 papers in Immunology. Recurrent topics in Robert Schmouder's work include Sphingolipid Metabolism and Signaling (33 papers), Renal Transplantation Outcomes and Treatments (24 papers) and Complement system in diseases (16 papers). Robert Schmouder is often cited by papers focused on Sphingolipid Metabolism and Signaling (33 papers), Renal Transplantation Outcomes and Treatments (24 papers) and Complement system in diseases (16 papers). Robert Schmouder collaborates with scholars based in United States, Switzerland and Germany. Robert Schmouder's co-authors include Philip J. Held, Robert A. Wolfe, Akinlolu Ojo, Friedrich K. Port, John M. Kovarik, P Burtin, Volker Brinkmann, Peter Heining, Thomas Baumruker and Shreeram Aradhye and has published in prestigious journals such as Blood, Nature Biotechnology and Nature Reviews Drug Discovery.

In The Last Decade

Robert Schmouder

89 papers receiving 5.3k citations

Hit Papers

Fingolimod (FTY720): discovery and development ... 1997 2026 2006 2016 2010 1997 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
    2010 1.0k citations Robert Schmouder et al. profile →
  2. DELAYED GRAFT FUNCTION: RISK FACTORS AND IMPLICATIONS FOR RENAL ALLOGRAFT SURVIVAL1
    1997 834 citations Akinlolu Ojo, Robert A. Wolfe et al. Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Schmouder United States 32 2.2k 1.3k 1.0k 765 740 93 5.4k
Bum Soon Choi South Korea 37 1.1k 0.5× 1.0k 0.8× 986 1.0× 506 0.7× 510 0.7× 194 4.7k
Jan Hinrich Bräsen Germany 35 2.0k 0.9× 669 0.5× 1.1k 1.1× 1.2k 1.6× 164 0.2× 134 5.4k
Nicolas Pallet France 34 1.2k 0.6× 709 0.5× 613 0.6× 285 0.4× 290 0.4× 123 3.4k
Wilfred Lieberthal United States 41 2.4k 1.1× 246 0.2× 909 0.9× 662 0.9× 251 0.3× 79 5.9k
David A. Power Australia 44 2.4k 1.1× 225 0.2× 1.1k 1.0× 940 1.2× 238 0.3× 187 7.0k
Joseph P. Gaut United States 29 1.1k 0.5× 435 0.3× 611 0.6× 749 1.0× 226 0.3× 72 3.3k
John R. Sedor United States 44 2.2k 1.0× 222 0.2× 540 0.5× 656 0.9× 286 0.4× 150 6.2k
Arnaud François France 31 842 0.4× 259 0.2× 524 0.5× 397 0.5× 158 0.2× 153 3.6k
Friedrich Thaiss Germany 35 1.2k 0.5× 317 0.2× 577 0.6× 1.2k 1.6× 102 0.1× 116 4.9k
Tullio Bertani Italy 39 1.2k 0.5× 424 0.3× 566 0.6× 603 0.8× 208 0.3× 95 6.2k

Countries citing papers authored by Robert Schmouder

Since Specialization
Citations

This map shows the geographic impact of Robert Schmouder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Schmouder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Schmouder more than expected).

Fields of papers citing papers by Robert Schmouder

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Schmouder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Schmouder. The network helps show where Robert Schmouder may publish in the future.

Co-authorship network of co-authors of Robert Schmouder

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Schmouder. A scholar is included among the top collaborators of Robert Schmouder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Schmouder. Robert Schmouder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Frías, Juan P., Robert Schmouder, Eric Lawitz, et al.. (2025). Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction–Associated Steatohepatitis. Alimentary Pharmacology & Therapeutics. 63(5). 637–647. 1 indexed citations
2.
Kulmatycki, Kenneth, Prasanna Kumar Nidamarthy, Elizabeth McNamara, et al.. (2025). Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals. Clinical and Translational Science. 18(10). e70361–e70361.
3.
Getz, Elise Burmeister, Richard R. Stein, Martin Fink, et al.. (2025). Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function. Clinical Pharmacology & Therapeutics. 117(5). 1358–1368.
4.
Schmouder, Robert, G. Junge, Prasanna Kumar Nidamarthy, & Kenneth Kulmatycki. (2023). #4463 JAPANESE AND WHITES SHARE SIMILAR IPTACOPAN PHARMACOKINETICS AND PHARMACODYNAMICS. Nephrology Dialysis Transplantation. 38(Supplement_1). 1 indexed citations
5.
Schmouder, Robert, G. Junge, Prasanna Kumar Nidamarthy, & Kenneth Kulmatycki. (2023). A First-in-Human, Phase 1 Study to Assess the Pharmacodynamic Properties of Single-Dose Iptacopan (CLNP023X2101). Blood. 142(Supplement 1). 4096–4096. 2 indexed citations
6.
DeLise, Anthony M., et al.. (2023). Results of Preclinical Animal Studies to Evaluate the Effect of Iptacopan on Pregnancy-Related Outcomes. Blood. 142(Supplement 1). 4094–4094. 1 indexed citations
7.
Schmouder, Robert, et al.. (2023). #4447 EFFECT OF RENAL IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS. Nephrology Dialysis Transplantation. 38(Supplement_1). 2 indexed citations
8.
Tamagnan, Gilles, Adriana Tavares, Olivier Barret, et al.. (2012). Brain distribution of BZM055, an analog of fingolimod (FTY720), in human. Multiple Sclerosis Journal. 18. 379–379. 10 indexed citations
9.
David, Olivier, Karin Meiser, Annamária Jakab, et al.. (2012). Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results. International Journal of Clinical Pharmacology and Therapeutics. 50(8). 540–544. 17 indexed citations
10.
Kovarik, John M., et al.. (2008). The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. European Journal of Clinical Pharmacology. 64(5). 457–463. 20 indexed citations
11.
Kovarik, John M., et al.. (2006). Everolimus drug interactions: application of a classification system for clinical decision making. Biopharmaceutics & Drug Disposition. 27(9). 421–426. 38 indexed citations
12.
Schmouder, Robert, Denise Serra, Yibin Wang, et al.. (2006). FTY720: Placebo‐Controlled Study of the Effect on Cardiac Rate and Rhythm in Healthy Subjects. The Journal of Clinical Pharmacology. 46(8). 895–904. 94 indexed citations
13.
Ettenger, Robert B., et al.. (2005). Pharmacokinetics of enteric‐coated mycophenolate sodium in stable pediatric renal transplant recipients. Pediatric Transplantation. 9(6). 780–787. 19 indexed citations
14.
Kovarik, John M., et al.. (2004). Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects. The Journal of Clinical Pharmacology. 44(5). 532–537. 76 indexed citations
15.
Kovarik, John M., et al.. (2004). Single‐dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. British Journal of Clinical Pharmacology. 57(5). 586–591. 67 indexed citations
16.
Kahan, Barry D., Janet L. Karlix, Ronald M. Ferguson, et al.. (2003). Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation. 76(7). 1079–1084. 111 indexed citations
17.
Budde, Klemens, Robert Schmouder, R. Brunkhorst, et al.. (2002). First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients. Journal of the American Society of Nephrology. 13(4). 1073–1083. 240 indexed citations
18.
Ojo, Akinlolu, Robert A. Wolfe, Philip J. Held, Friedrich K. Port, & Robert Schmouder. (1997). DELAYED GRAFT FUNCTION: RISK FACTORS AND IMPLICATIONS FOR RENAL ALLOGRAFT SURVIVAL1. Transplantation. 63(7). 968–974. 834 indexed citations breakdown →
19.
Turgeon, D. Kim, Alan B. Leichtman, Robert Schmouder, et al.. (1994). PREDICTION OF INTERPATIENT AND INTRAPATIENT VARIATION IN OG 37–325 DOSING REQUIREMENTS BY THE ERYTHROMYCIN BREATH TEST. Transplantation. 57(12). 1736–1741. 19 indexed citations
20.
Julius, Stevo, Lisa Krause, Nicholas J. Schork, et al.. (1991). Hyperkinetic borderline hypertension in Tecumseh, Michigan. Journal of Hypertension. 9(1). 77–84. 181 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bum Soon Choi Breakdown of academic impact, for papers by Jan Hinrich Bräsen Breakdown of academic impact, for papers by Nicolas Pallet Breakdown of academic impact, for papers by Wilfred Lieberthal Breakdown of academic impact, for papers by David A. Power Breakdown of academic impact, for papers by Joseph P. Gaut Breakdown of academic impact, for papers by John R. Sedor Breakdown of academic impact, for papers by Arnaud François Breakdown of academic impact, for papers by Friedrich Thaiss Breakdown of academic impact, for papers by Tullio Bertani
Rankless by CCL
2026